RT Journal Article
SR Electronic
T1 Method for Active Pandemic Curve Management (MAPCM)
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.06.20055699
DO 10.1101/2020.04.06.20055699
A1 Odendaal, Willem G.
YR 2020
UL http://medrxiv.org/content/early/2020/04/22/2020.04.06.20055699.abstract
AB The COVID-19 pandemic of 2020 prompted stringent mitigation measures to “flatten the curve” quickly leading to an asphyxiated US economy as a national side effect. There are severe drawbacks to this strategy. The resulting flattened curve remains exponential and always under utilizes available healthcare capacity with a chance of still overburdening it. Moreover, while a mitigation strategy involving isolation and containment can scale down infections, it not only prolongs the outbreak significantly, but also leaves a susceptible population in its wake that’s ripe for a secondary outbreak. Since economic activity is inversely proportional to mitigation, curtailing the outbreak with sustained mitigation can stifle the economy severely with disastrous repercussions. Full mitigation for the duration of an outbreak is therefore unsustainable and, overall, a poor solution with potentially catastrophic consequences that could’ve been avoided. A new strategy, coined a “Method for Active Pandemic Curve Management”, or MAPCM, presented herein can shape the outbreak curve in a controlled manner for optimal utilization of healthcare resources during the pandemic, while drastically shortening the outbreak duration compared to mitigation by itself without trading off lives. This method allows mitigation measures to be relaxed gradually from day one, which enables economic activity to resume gradually from the onset of a pandemic. Since outbreak curves (such as hospitalizations) can be programmed using this method, they can also be shaped to accommodate changing needs during the outbreak; and to build herd immunity without the damaging side effects. The method can also be used to ease out of containment. MAPCM is a method and not a model. It is compatible with any appropriate outbreak model; and herein it is illustrated in examples using a hybrid logistic model.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThere were no trials in the study.Funding StatementThis work was not fundedAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is publicly available and has been widely distributed. http://coronavirus.gov